Brad Margus

Brad Margus has a varied and extensive work experience in the biotechnology industry. Brad is the Co-founder and Board Chair of Cerevance since December 2022. Prior to that, they served as the Co-founder and Executive Chairman from May 2022 to November 2022, and as the Co-founder and CEO from October 2016 to April 2022.

Before Cerevance, Brad Margus co-founded and served as Chairman of the A-T Children's Project starting from 1993. In 2013, they co-founded Genome Bridge and held the position of Chief Executive Officer until 2014. From 2009 to 2013, they were the Co-founder and CEO of Envoy Therapeutics.

Additionally, Brad Margus was involved in the establishment of Perlegen Sciences. Brad served as the Co-founder and Vice Chairman from May 2008 to October 2008, as the Co-founder and Executive Vice Chairman from May 2007 to April 2008, and as the Co-founder and Chief Executive Officer from April 2000 to April 2007.

Overall, Brad Margus has demonstrated their expertise and leadership abilities through their various co-founder, executive, and board positions in multiple biotechnology companies.

Brad Margus attended Harvard Business School from 1984 to 1986, where they obtained an MBA degree. The field of study for their MBA degree is not provided.